Akebia Therapeutics, Inc. (AKBA)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 0.3317 |
| Open | 0.3170 |
| Bid | 0.3200 x 900 |
| Ask | 0.3425 x 800 |
| Day's range | 0.3010 - 0.3310 |
| 52-week range | 0.3000 - 3.3500 |
| Volume | |
| Avg. volume | 6,459,658 |
| Market cap | 58.832M |
| Beta (5Y monthly) | 1.49 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.5990 |
| Earnings date | 02 Nov 2022 - 07 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.63 |
- Zacks
Akebia Therapeutics (AKBA) Surpasses Q2 Earnings and Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 174.19% and 158.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -29.63% and 39.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Zoetis (ZTS) Tops Q1 Earnings and Revenue Estimates
Zoetis (ZTS) delivered earnings and revenue surprises of 8.20% and 0.88%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
© 2022 Yahoo. All rights reserved.
